Total Payments
$2,440
2024 Payments
$533.14
Companies
19
Transactions
27
Medicare Patients
2,350
Medicare Billing
$388,126
Payment Breakdown by Category
Consulting$910.00 (37.3%)
Food & Beverage$883.85 (36.2%)
Other$450.00 (18.4%)
Education$196.30 (8.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $910.00 | 1 | 37.3% |
| Food and Beverage | $883.85 | 22 | 36.2% |
| Honoraria | $450.00 | 1 | 18.4% |
| Education | $196.30 | 3 | 8.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $928.97 | 2 | $0 (2023) |
| Sirtex Medical Inc | $569.46 | 2 | $0 (2017) |
| Monteris Medical Corporation | $124.72 | 1 | $0 (2022) |
| Incyte Corporation | $111.85 | 2 | $0 (2024) |
| Sumitomo Pharma America, Inc. | $102.42 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $102.34 | 1 | $0 (2024) |
| Lilly USA, LLC | $100.39 | 1 | $0 (2021) |
| GE HEALTHCARE | $96.22 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $58.83 | 3 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $38.48 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $533.14 | 11 | Incyte Corporation ($111.85) |
| 2023 | $39.82 | 2 | Novartis Pharmaceuticals Corporation ($20.85) |
| 2022 | $1,091 | 4 | Genentech USA, Inc. ($910.00) |
| 2021 | $112.31 | 2 | Lilly USA, LLC ($100.39) |
| 2019 | $34.23 | 2 | Amgen Inc. ($28.37) |
| 2018 | $25.94 | 2 | Clovis Oncology, Inc. ($25.94) |
| 2017 | $604.06 | 4 | Sirtex Medical Inc ($569.46) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $102.34 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $13.91 | General |
| 07/12/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, LORBRENA | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $83.99 | General |
| 06/27/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/25/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $102.42 | General |
| Category: HORMONE THERAPY | ||||||
| 06/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.83 | General |
| 05/10/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $27.86 | General |
| Category: Hematology/Oncology | ||||||
| 05/10/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $22.96 | General |
| 05/08/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: Oncology | ||||||
| 02/27/2024 | GE HEALTHCARE | — | Food and Beverage | In-kind items and services | $96.22 | General |
| 11/06/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Oncology | ||||||
| 03/14/2023 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: BioOncology | ||||||
| 10/05/2022 | Monteris Medical Corporation | Neuroblate (Device) | Food and Beverage | In-kind items and services | $124.72 | General |
| Category: Neuroblate | ||||||
| 09/16/2022 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: Oncology | ||||||
| 07/26/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $38.48 | General |
| Category: ONCOLOGY | ||||||
| 04/07/2022 | Genentech USA, Inc. | Perjeta (Biological), Kadcyla, Phesgo | Consulting Fee | Cash or cash equivalent | $910.00 | General |
| Category: BioOncology | ||||||
| 08/09/2021 | Lilly USA, LLC | — | Education | In-kind items and services | $100.39 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 10/09/2019 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $5.86 | General |
| Category: Oncology | ||||||
| 10/02/2019 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $28.37 | General |
| Category: Oncology | ||||||
| 03/13/2018 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: Oncology | ||||||
| 02/13/2018 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: Oncology | ||||||
| 12/06/2017 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Oncology | ||||||
| 11/09/2017 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 572 | 1,154 | $320,843 | $96,560 |
| 2022 | 9 | 656 | 1,323 | $281,992 | $107,745 |
| 2021 | 7 | 548 | 1,101 | $226,215 | $96,173 |
| 2020 | 8 | 574 | 1,183 | $238,730 | $87,647 |
Total Patients
2,350
Total Services
4,761
Medicare Billing
$388,126
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 94 | 373 | $125,078 | $39,490 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 267 | 485 | $115,537 | $32,384 | 28.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 69 | 153 | $28,487 | $9,354 | 32.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 52 | 52 | $16,096 | $4,749 | 29.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 30 | 30 | $12,284 | $3,934 | 32.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 29 | 30 | $10,567 | $3,032 | 28.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $9,315 | $2,424 | 26.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 13 | $3,480 | $1,195 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 99 | 371 | $100,199 | $39,806 | 39.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 283 | 515 | $97,305 | $34,942 | 35.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 102 | 259 | $33,558 | $13,940 | 41.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 61 | 61 | $17,671 | $5,769 | 32.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 28 | $9,832 | $4,323 | 44.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 30 | 30 | $11,140 | $4,067 | 36.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 29 | $7,925 | $3,090 | 39.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 18 | $3,311 | $1,448 | 43.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 11 | 12 | $1,051 | $359.66 | 34.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 93 | 385 | $94,325 | $41,941 | 44.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 287 | 496 | $84,320 | $34,348 | 40.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 60 | 60 | $16,800 | $5,669 | 33.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 46 | 94 | $10,810 | $5,393 | 49.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 25 | 25 | $7,875 | $4,049 | 51.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $7,810 | $2,797 | 35.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 19 | $4,275 | $1,976 | 46.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 100 | 395 | $96,775 | $34,855 | 36.0% |
About Maria Juarez, M. D
Maria Juarez, M. D is a Medical Oncology healthcare provider based in Duncanville, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447297965.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Maria Juarez, M. D has received a total of $2,440 in payments from pharmaceutical and medical device companies, with $533.14 received in 2024. These payments were reported across 27 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($910.00).
As a Medicare-enrolled provider, Juarez has provided services to 2,350 Medicare beneficiaries, totaling 4,761 services with total Medicare billing of $388,126. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Duncanville, TX
- Active Since 06/01/2006
- Last Updated 08/12/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1447297965
Products in Payments
- Perjeta (Biological) $910.00
- SIR-Spheres Microspheres (Device) $569.46
- Neuroblate (Device) $124.72
- ORGOVYX (Drug) $102.42
- OJJAARA (Drug) $102.34
- LIBTAYO (Biological) $38.48
- Rubraca (Drug) $31.80
- Kyprolis (Biological) $28.37
- JAKAFI (Drug) $27.86
- IMFINZI (Biological) $24.23
- IMFINZI (Drug) $23.83
- XARELTO (Drug) $21.30
- KISQALI (Drug) $20.85
- Phesgo (Biological) $18.97
- INLYTA (Drug) $18.08
- Xospata (Drug) $17.45
- BRILINTA (Drug) $10.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.